AUR-AER6-TTM5-A-1-1-R-A742-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.370
- APICAL_JUNCTION+0.350
- HYPOXIA+0.340
- NOTCH_SIGNALING+0.320
- ANGIOGENESIS+0.310
- HEDGEHOG_SIGNALING+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.290
- ESTROGEN_RESPONSE_EARLY+0.270
- WNT_BETA_CATENIN_SIGNALING+0.240
- GLYCOLYSIS+0.190
Top 10 suppressed
- E2F_TARGETS-0.370
- PROTEIN_SECRETION-0.360
- MYC_TARGETS_V1-0.280
- G2M_CHECKPOINT-0.270
- ALLOGRAFT_REJECTION-0.250
- UNFOLDED_PROTEIN_RESPONSE-0.240
- SPERMATOGENESIS-0.230
- BILE_ACID_METABOLISM-0.220
- DNA_REPAIR-0.200
- KRAS_SIGNALING_UP-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AER6-TTM10-A-1-1-R-A742-41 | — | C | 0.827 |
| 2 | a4322796-9189-48c2-9e7c-7b1493b5799a | — | — | 0.807 |
| 3 | 9b308588-5e79-46ab-b186-6edd686695c6 | — | — | 0.773 |
| 4 | 3843de1d-0eaa-48af-be58-903fcf2e5f89 | — | — | 0.767 |
| 5 | 1e82995c-f318-4225-96d4-f1e98bcbf60b | — | — | 0.755 |
| 6 | R314 | — | — | 0.751 |
| 7 | SRR23303772 | — | — | 0.746 |
| 8 | C3N-02339 | — | cohortSQ1 | 0.742 |
| 9 | GSM6454741 | — | D | 0.741 |
| 10 | SRR8613770 | — | E | 0.739 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.350 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.160 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.120 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |